Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 24, 2020, Gilead announced the FDA approval of Tecartus (brexucabtagene autoleucel), for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
Return to publications